Sponsor hub

University of Pennsylvania clinical trial failures

Review 90 stopped clinical trials from University of Pennsylvania, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 3 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials90
Likely biological signals3
Shown below90

Dominant stop reasons

OPERATIONAL
61
OTHER/UNKNOWN
26
EFFICACY/FUTILITY
2
SAFETY
1

Notable sponsors

University of Pennsylvania
90

Related phases

Phase I
29
Phase II
27
Unknown
14
Early Phase I
9
Phase IV
8

Crawlable stopped-trial records

Open Explore

Showing up to 90 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04221061: 18F-FluorThanatrace (PET/CT) in Glioblastoma

Early Phase I Glioblastoma trial by University of Pennsylvania. Stop reason: OPERATIONAL.

Companion treatment trial closed early with negative results. No imaging study participants completed the full study imaging planned due to logistical difficulties.

NCT05179772: Olanzapine in OUD Patients

Phase II Opioid Use Disorder trial by University of Pennsylvania. Stop reason: OTHER/UNKNOWN.

NIDA has advised us to terminate this protocol due to the difficulties in finding appropriate subjects.

NCT02074904: Topiramate's Effects on Heavy Drinking

Phase II Alcohol Drinking trial by University of Pennsylvania. Stop reason: OTHER/UNKNOWN.

We terminated the study to run it as a sub-study of NCT02371889, which is a 13 week, placebo controlled, double-blind, trial of topiramate in heavy drinkers.

NCT02003664: A Study of Baclofen ER

Phase II Cocaine Dependence trial by University of Pennsylvania. Stop reason: OPERATIONAL.

This study never started due to delays in medication development